Get started

Corvus Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

CRVS chart

Key stats

Market capitalization
74.918MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.84USD
Net income
−41.307MUSD
Revenue
—
Shares float
48.966M
Beta
1.21

About Corvus Pharmaceuticals, Inc.

Sector
Health Technology
CEO
Richard A. Miller
Headquarters
Burlingame
Website
corvuspharma.com
Employees
29
Founded
2014
ISIN
US2210151005

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Ideas

CRVS Short Entry and CoverI put an order our premarket to go short CRVS at the 3.50 level at 3.45. With a target half way back to the 3.00 level at 3.21. The reason I made my target half way to the 3.00 support is not entirely clear to me. Something about how the stock is not very extended, and how volume has been low. it fe
KalaGhazi | Corvus Pharmaceuticals Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment On Wednesday, the company said it will present new data for CPI-818 at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland from June 13 to 17.
Long
$CRVSCorvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer. Corvus Pharmaceuticals, Inc., a clinical stage biopharm
Long
$CRVS Corvus Pharmaceuticals Potential Friday Pump Pt's Hopefully you find the chart helpful in terms of Supports & Resistance etc. we refrain from adding commentary on the chart as that is reserved for our members and we are very conscious of not giving financial or trading advice. Thank you for taking time to consult our chart and we would really a
$CRVS Bullish Bat CRVS has a Bullish Bat HOP Levels: .24 cents .382 fib $3.75 .618 fib $4.93 on the weekly chart it is a strong green candle, but as for the Daily candle we do have a major gap, meaning we could refill that GAP between $2.53 - $3.57
Long
CRVS - Long Setup Downward channel breakout insider a larger downward channel. Break 2.86 Target 3.43 and Target 2 5.43. Would consider stop of 2.37. Larger risk as stock as already just broken out. January $5.00 calls had 262 contracts traded on Friday. Price is 0.19 cents. $2.50 calls are 0.70.
Long
My CRVS Price TargetsHello all, As you all may have noticed from doing your research that there has been a quantifiable spike in insider buying by the President and Director of Orbimed Advisors. On February 17th, 2021 there was an Initial Public Offering at $3.50/share. I have not made any extensive due diligence on
Long
2
$CRVS is gonna to fall todayPupm&Dump trading strategy idea. $CRVS is rising without clear preconditions today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $5,51; stop-loss — $6,3. Information about
4

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.3Good
Learn more

See all brokers